Page last updated: 2024-11-05

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Atherogenesis

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Atherogenesis in 1 studies

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tsou, CY1
Chen, CY1
Zhao, JF1
Su, KH1
Lee, HT1
Lin, SJ1
Shyue, SK1
Hsiao, SH1
Lee, TS1

Other Studies

1 other study available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Atherogenesis

ArticleYear
Activation of soluble guanylyl cyclase prevents foam cell formation and atherosclerosis.
    Acta physiologica (Oxford, England), 2014, Volume: 210, Issue:4

    Topics: Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; Cell Line; Enzyme A

2014